R Squared Ltd Raises Stock Holdings in Sanofi $SNY

R Squared Ltd grew its position in Sanofi (NASDAQ:SNY) by 189.9% in the 1st quarter, Holdings Channel.com reports. The fund owned 26,030 shares of the company’s stock after acquiring an additional 17,050 shares during the quarter. Sanofi comprises about 0.7% of R Squared Ltd’s holdings, making the stock its 19th largest position. R Squared Ltd’s holdings in Sanofi were worth $1,254,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Flagship Harbor Advisors LLC purchased a new stake in Sanofi in the 4th quarter valued at $25,000. Physician Wealth Advisors Inc. grew its position in Sanofi by 180.5% during the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock worth $28,000 after purchasing an additional 379 shares during the last quarter. Leonteq Securities AG grew its position in Sanofi by 95.8% during the 1st quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after purchasing an additional 297 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new position in Sanofi in the third quarter valued at $29,000. Finally, Palisade Asset Management LLC acquired a new position in Sanofi in the third quarter valued at $30,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have recently weighed in on SNY. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, March 19th. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Morgan Stanley set a $52.00 price objective on Sanofi in a research note on Friday, May 1st. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Finally, BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price on the stock. in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $51.00.

Sanofi Stock Performance

Shares of SNY stock traded up $0.62 during mid-day trading on Tuesday, hitting $43.23. The stock had a trading volume of 1,172,429 shares, compared to its average volume of 3,655,331. Sanofi has a fifty-two week low of $40.89 and a fifty-two week high of $52.68. The firm has a market cap of $104.81 billion, a PE ratio of 12.08, a PEG ratio of 1.07 and a beta of 0.34. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. The company’s 50-day simple moving average is $43.59 and its 200-day simple moving average is $45.79.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were given a $2.4225 dividend. The ex-dividend date was Monday, May 4th. This is an increase from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. Sanofi’s payout ratio is 49.16%.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.